Intraocular Steroid After Cataract Surgery Study
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00478764 |
Recruitment Status
:
Completed
First Posted
: May 25, 2007
Last Update Posted
: May 25, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cataract | Drug: intraocular triamcinolone and gatifloxicin | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 41 participants |
Allocation: | Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Intracameral Use of Triamcinolone and Gatifloxacin Versus Standard Postoperative Steroid and Antibiotic Eye Drops After Cataract Surgery |
Study Start Date : | March 2006 |
Actual Study Completion Date : | April 2007 |

- visual acuity [ Time Frame: 90 days ]
- intraocular inflammation [ Time Frame: 90 days ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 80 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Inclusion criteria for patients to enter the study included age 40 to 80 years, clinically significant cataract in both eyes, the patient’s willingness to enter the study and have cataract surgery preformed on each eye in a sequentially within a two or three week time frame.
Exclusion Criteria:
- Exclusion criteria included a history of glaucoma, retinopathy of any type, pseudoexfoliation, other significant ocular co morbidity and systemic diabetes.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00478764
United States, Wisconsin | |
Davis Duehr Dean Baraboo | |
Baraboo, Wisconsin, United States, 53913 |
Principal Investigator: | Jonathan G Stock, MD | Dean Health Systems |
Publications:
ClinicalTrials.gov Identifier: | NCT00478764 History of Changes |
Other Study ID Numbers: |
IOSS |
First Posted: | May 25, 2007 Key Record Dates |
Last Update Posted: | May 25, 2007 |
Last Verified: | May 2007 |
Keywords provided by Dean Health System:
intraocular triamcinolone gatifloxicin inflammation visual acuity |
Additional relevant MeSH terms:
Cataract Capsule Opacification Lens Diseases Eye Diseases Triamcinolone hexacetonide Triamcinolone Triamcinolone Acetonide Triamcinolone diacetate Anti-Inflammatory Agents |
Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Immunosuppressive Agents Immunologic Factors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |